The SGLT2 inhibitor empagliflozin (Jardiance) is now available in combination with metformin as Synjardy for the treatment of type II diabetes.
When metformin alone is inadequate and patients need a combination of tablets, you can now use Synjardy instead. Treatment with empagliflozin in combination with metformin, with or without other antidiabetic agents, led to clinically relevant improvements in HbA1c, fasting plasma glucose, body weight and blood pressure.
